BlackRock, Inc. 13D and 13G filings for Evofem Biosciences, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-07-12 08:29 am Sale | 2021-06-30 | 13G | Evofem Biosciences, Inc. EVFM | BlackRock Inc. BLK | 1,811 2.300% | -970 (-34.87%) | Filing |
| 2021-02-02 3:13 pm Purchase | 2020-12-31 | 13G | Evofem Biosciences, Inc. EVFM | BlackRock Inc. BLK | 2,781 6.400% | 1,776 (+176.77%) | Filing |
| 2020-06-09 4:33 pm Sale | 2020-05-31 | 13G | Evofem Biosciences, Inc. EVFM | BlackRock Inc. BLK | 1,005 3.000% | -3,230 (-76.27%) | Filing |
| 2020-03-09 4:31 pm Purchase | 2020-02-29 | 13G | Evofem Biosciences, Inc. EVFM | BlackRock Inc. BLK | 4,235 17.000% | 4,235 (New Position) | Filing |